Home
Live Updates
Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma : comparemela.com
Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase
Related Keywords
United States ,
Paris ,
France General ,
France ,
American ,
Thomas Larsen ,
Evan Berland ,
Timothy Gilbert ,
Dietmar Berger ,
Nicolas Obrist ,
Felix Lauscher ,
Tarik Elgoutni ,
Corentine Driancourt ,
European Union ,
Drug Administration ,
Nasdaq ,
American Society Of Clinical Oncology ,
Global Head Of Development At Sanofi ,
European Hematology Association ,
World Health Organization ,
Euronext ,
Clinical Oncology ,
Annual Meeting ,
Priority Review ,
Biologics License Application ,
Medical Officer ,
Global Head ,
Hematology Association ,
Nonproprietary Naming ,
Biological Products Guidance ,
Private Securities Litigation Reform Act ,
Statement Regarding Forward Looking ,
Accessed March ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.